Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates

<p class="MsoNormal">Featuring an interview with Dr Priyanka Sharma<span class="normaltextrun">,</span> including the following topics:</p> <ul> <li>T-DXd versus trastuzumab emtansine for high-risk HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis of the DESTINY-Breast05 trial (0:00) <ul> <li><span class="normaltextrun">Geyer C et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. ESMO 2025;</span><a href="https://www.sciencedirect.com/science/article/abs/pii/S092375342504791X" target="_blank" rel="noopener"><span class= "normaltextrun">Abstract LBA1</span></a><span class= "normaltextrun">. </span><span class="eop"> </span></li> </ul> </li> <li>DESTINY-Breast11 trial: Neoadjuvant T-DXd alone or...